Tenax Therapeutics, Inc. (TENX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

181.91 k

Shareholding (Mar 2025)

FII

1.43%

Held by 9 FIIs

DII

83.54%

Held by 3 DIIs

Promoter

12.22%

How big is Tenax Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Tenax Therapeutics, Inc. has a market capitalization of 23.56 million and reported net sales of 0.00 million with a net profit of -24.22 million over the last four quarters. Shareholder's funds were 91.99 million, and total assets were 96.69 million.

What does Tenax Therapeutics, Inc. do?

22-Jun-2025

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing products for critical care, particularly acutely decompensated heart failure. It has a market cap of $23.56 million and reported a net profit loss of $10 million as of March 2025.

Who are in the management team of Tenax Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Tenax Therapeutics, Inc. includes Dr. Ronald Blanck (Independent Chairman), Mr. Anthony DiTonno (CEO), and Directors Mr. Steven Boyd, Mr. Keith Maher, Mr. James Mitchum, Mr. Gerald Proehl, and Mr. Gregory Pepin. They oversee the company's strategic direction and operations.

Is Tenax Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Tenax Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and KST indicators, despite some bearish signals from daily moving averages and mixed Dow Theory signals, while outperforming the S&P 500 in the short term but lagging in the long term.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 28 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.02

Return on Equity

-30.47%

Price to Book

0.27

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

55.32%

6 Months

58.84%

1 Year

54.8%

2 Years

-68.72%

3 Years

-95.76%

4 Years

-99.5%

5 Years

-99.52%

Tenax Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Tenax Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Tenax Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the overall positive sentiment. The KST is bullish on both weekly and monthly time frames, while the OBV indicates a mildly bullish stance in both periods as well. However, the daily moving averages show a mildly bearish trend, which tempers the overall bullish outlook. The Dow Theory presents a mildly bullish signal on the weekly and mildly bearish on the monthly, indicating mixed signals. In terms of performance, Tenax has outperformed the S&P 500 over the past week and month, returning 4.40% and 6.66% respectively, compared to the S&P 500's 1.05% and 2.33%. However, the longer-term returns are significantly negative over 3 and 5 years, contrasting sharply with the S&P 500's positive performance in those period...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-209.11%

EBIT to Interest (avg)

-18.13

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

63.20%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.23

EV to EBIT

3.21

EV to EBITDA

3.21

EV to Capital Employed

40.03

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1248.78%

ROE (Latest)

-22.15%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (2.81%)

Foreign Institutions

Held by 9 Foreign Institutions (1.43%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -200.00% vs -227.27% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.80",
          "val2": "-3.70",
          "chgp": "-218.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.80",
          "val2": "-3.60",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -128.57% vs 30.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.50",
          "val2": "-8.20",
          "chgp": "-137.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.60",
          "val2": "-7.70",
          "chgp": "-128.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.80

-3.70

-218.92%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-10.80

-3.60

-200.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -200.00% vs -227.27% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-19.50

-8.20

-137.80%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.60

-7.70

-128.57%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -128.57% vs 30.00% in Dec 2023

All Annual Results

Company CV

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Company Coordinates

Company Details

One Copley Parkway, Suite 490 , MORRISVILLE NC : 27560

Tel: 1 919 80644141 919 8552112

http://www.tenaxthera.com/

Registrar Details

Tenax Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Tenax Therapeutics, Inc.?

Watch in Real-Time

What does Tenax Therapeutics, Inc. do?

Who are in the management team of Tenax Therapeutics, Inc.?

Is Tenax Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Tenax Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Tenax Therapeutics, Inc.

Company Coordinates